SEC Form 4 · accession 0001123292-17-001439
OSIRIS THERAPEUTICS, INC. · OSIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda Palczuk
Officer — President & CEO
Period of report
Jul 10, 2017
Accepted (ET)
Sep 21, 2017 · 3:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360886
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $6.67 | Jul 10, 2017 | A | 25,000 | A | Jul 10, 2018 | Jul 10, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F16,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date.